Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
131 Leser
Artikel bewerten:
(0)

Oxford Immunotec: Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference

OXFORD, United Kingdom and MARLBOROUGH, Mass., 2017-11-21 15:15 CET (GLOBE
NEWSWIRE) --
Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today announced that
Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual
Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m.
EST. The conference will be held at the Lotte New York Palace. 

A live webcast of the presentation will be available online from the investor
relations page of the Company's corporate website at www.oxfordimmunotec.com. A
webcast replay will be available approximately two hours after the live
presentation and will be archived on the website for approximately 90 days. 

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company
focused on developing and commercializing proprietary tests for the management
of underserved immune-regulated conditions.  The Company's first product is the
T-SPOT.TB test, which is used to test for tuberculosis infection.  The
T-SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China.  The Company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics.  Also obtained through these acquisitions is the Company's third
product line focused on screening for Babesia in donated blood, for which the
Company is currently seeking FDA licensure.  The Company's fourth product line
is focused on the transplantation market.  The Company is headquartered near
Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at
www.oxfordimmunotec.com. 

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. 
Immunetics is a trademark of Immunetics, Inc. 

CONTACT:

For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com
Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2017 GlobeNewswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.